Transcode Therapeutics (RNAZ) Cash from Financing Activities (2020 - 2025)

Transcode Therapeutics (RNAZ) has 6 years of Cash from Financing Activities data on file, last reported at $23.1 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 226.52% year-over-year to $23.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31.5 million (up 92.2% YoY) and the FY2025 annual result came in at $31.5 million, up 92.2% from the prior year.
• Cash from Financing Activities grew to $23.1 million in Q4 2025, from -$455726.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $25.6 million in Q3 2021 to a low of -$455726.0 in Q3 2025.
• A 5-year average of $5.0 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 41963.6% — and 2025, when it slumped 118.63%.
• Tracing RNAZ's Cash from Financing Activities over 5 years: stood at $9485.0 in 2021, then jumped by 2280.78% to $225817.0 in 2022, then surged by 333.16% to $978153.0 in 2023, then jumped by 624.02% to $7.1 million in 2024, then soared by 226.52% to $23.1 million in 2025.
• The last three Cash from Financing Activities figures came in at $23.1 million (Q4 2025), -$455726.0 (Q3 2025), and $8.9 million (Q1 2025), per Business Quant data.